

Amendments to the Claims

This listing of the claims will replace all prior versions and listing of claims in this application.

Listing of Claims

1. (Currently Amended) A solid pharmaceutical formulation comprising:
 - a. an active pharmaceutical ingredient which is a quinolone antibiotic, **selected from the group consisting of pradofloxacin, a pradofloxacin salt or a hydrate of pradofloxacin or of its salt,**
 - b. 4 to 20 % by weight of a flavoring which is a mixture of proteins, fats, and carbohydrates, and,
 - c. 1.5% to 15% by weight of colloidal silicon dioxide based on the total weight of the finished formulation wherein the ratio by weight of colloidal silicon dioxide to flavoring is 1:4 to 1:1, and wherein the formulation excludes starch.
2. (Canceled)
3. (Canceled)
4. (Previously Presented) A process for producing the solid pharmaceutical formulation according to claim 1, in which the flavoring is granulated with the colloidal silicon dioxide and with one or more active ingredients and pharmaceutically customary additives and/or excipients.
5. (Canceled)
6. (Canceled)
7. (Canceled)

8. (Canceled)
9. (Previously Presented) The solid pharmaceutical formulation according to claim 1, comprising at least 2.5% by weight silicon dioxide.
10. (Previously Presented) The solid pharmaceutical formulation according to claim 1, comprising not more than 15% by weight of silicon dioxide.
11. (New) A solid pharmaceutical formulation comprising:
 - a. 15 % by weight pradofloxacin;
 - b. 35 % by weight microcrystalline cellulose;
 - c. 24 % by weight lactose;
 - d. 5 % by weight polyvinylpyrrolidone;
 - e. 10% by weight flavoring which is a mixture of proteins, fats, and carbohydrates;
 - f. 7.5 % by weight croscarmellose sodium;
 - g. 2.5 % by weight colloidal silicon dioxide; and,
 - h. 1.0% by weight magnesium stearate and wherein the formulation excludes starch.